Thomas Jonassen, MD, Chair

CHAIRMAN

Thomas Jonassen is an experienced biotech entrepreneur, having founded a number of successful biotech companies. He is the former co-founder and Chief Science Officer of Action Pharma (sold to Abbvie in 2012), TXP-Pharma (main asset sold to Questcor Pharmaceuticals in 2015) and presently also serves as CSO at SynAct Pharma, a biotech company focused on novel therapeutics for inflammatory joint disorders. In addition to these roles, Dr. Jonassen is associate professor at the University of Copenhagen in the department of Cardiovascular Pharmacology and an honorary professor at William Harvey Research Institute at the Queen Mary University in London.

Jeppe Øvli Øvlesen, MBA

DIRECTOR

Jeppe Øvlesen is an experienced biotech entrepreneur and has been involved as founder/CEO/Chairman in a string of successful companies including Action Pharma, CLC Bio, Cetrea, ChemoMetec, Monsenso, PNN Medical, and TXP Pharma.

Mr. Øvlesen is co-founder and presently serves as CEO of SynAct Pharma, which is listed on Nasdaq Stockholm.

Henrik Stage, MS

DIRECTOR

Henrik Stage has held roles such as VP, CFO, and CEO in a number of successful international corporations, including Carlsberg Breweries, Hempel Intl, and Santaris Pharma. At Santaris Mr. Stage served as CEO and CFO and closed partnerships with Pfizer, Wyeth, Shire, GlaxoSmithKline and managed the sale and asset transfer to Roche. Currently Mr. Stage serves as CFO at RhoVac and SynAct Pharma.

Sven Jacobson, MBA

DIRECTOR

Sven Jacobson is a life science entrepreneur. He has co-founded and serves as CEO of Woolsey Pharmaceuticals, a privately held, clinical stage pharmaceutical company.

Previously, Mr. Jacobson co-founded and served on the board of Access Scientific, Cure Therapeutics and St. Camillus Medical and is currently a Director of the Board of Critical Diagnostics and a Partner at Carrot Capital Healthcare Ventures

Rod Flower, Prof. Emer.

DIRECTOR

Dr. Flower, a distinguished pharmacologist, graduated with first-class honors in physiology from the University of Sheffield in 1971. After postgraduate training with Nobel Laureate John Vane, he spent over a decade at the Wellcome Foundation before becoming the Chair of Pharmacology at the University of Bath in 1985. He is the co-founder of the William Harvey Research Institute and was Institute Director from 2000-2004. Dr. Flower made significant contributions to understanding the biology of annexins and their anti-inflammatory properties and has published over 350 papers and books. He has received numerous national and international awards, including the 2005 Lifetime Achievement Award from the International Association of Inflammation Societies.

Thomas Jonassen, MD, Chair

CHAIRMAN

Thomas Jonassen is an experienced biotech entrepreneur, having founded a number of successful biotech companies. He is the former co-founder and Chief Science Officer of Action Pharma (sold to Abbvie in 2012).

During that time, Symphogen grew from a start-up to one of the most innovative and successful clinical-stage biotechs in Europe. Dr. Drejer now serves on the boards of Zealand Pharma, BioPorto, Bioneer, Antaq Therapeutics among others.

Jeppe Øvli Øvlesen, MBA

DIRECTOR

Jeppe Øvlesen is an experienced biotech entrepreneur and has been involved as founder/CEO/Chairman in a string of successful companies including Action Pharma, CLC Bio, Cetrea, ChemoMetec, Monsenso, PNN Medical, and TXP Pharma.

Mr. Øvlesen is co-founder and presently serves as CEO of SynAct Pharma, which is listed on the Swedish small-cap exchange Aktietorget.

Henrik Stage, MS

DIRECTOR

Henrik Stage has held roles such as VP, CFO, and CEO in a number of successful international corporations, including Carlsberg Breweries, Hempel Intl, and Santaris Pharma.

At Santaris Mr. Stage served as CEO and CFO and closed partnerships with Pfizer, Wyeth, Shire, GlaxoSmithKline and managed the sale and asset transfer to Roche. Currently Mr. Stage serves as CFO at RhoVac and SynAct Pharma.

Sven Jacobson, MBA

DIRECTOR

Sven Jacobson is a life science entrepreneur. He has co-founded and serves as CEO of Woolsey Pharmaceuticals, a privately held, clinical stage pharmaceutical company. .

Previously, Mr. Jacobson co-founded and served on the board of Access Scientific, Cure Therapeutics and St. Camillus Medical and is currently a Director of the Board of Critical Diagnostics and a Partner at Carrot Capital Healthcare Ventures

Professor Roderick Flower, Prof. Emer.

DIRECTOR

Dr. Flower, a distinguished pharmacologist, graduated with first-class honors in physiology from the University of Sheffield in 1971. After postgraduate training with Nobel Laureate John Vane, he spent over a decade at the Wellcome Foundation before becoming the Chair of Pharmacology at the University of Bath in 1985.

He is the co-founder of the William Harvey Research Institute and was Institute Director from 2000-2004.

Dr. Flower made significant contributions to understanding the biology of annexins and their anti-inflammatory properties and has published over 350 papers and books. He has received numerous national and international awards, including the 2005 Lifetime Achievement Award from the International Association of Inflammation Societies.

Previously, Mr. Jacobson co-founded and served on the board of Access Scientific, Cure Therapeutics and St. Camillus Medical and is currently a Director of the Board of Critical Diagnostics and a Partner at Carrot Capital Healthcare Ventures